Literature DB >> 18057972

Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.

M Fleischhacker1, C Radecke, B Schulz, M Ruhnke.   

Abstract

OBJECTIVES: To analyze the effects of a high concentration of three antifungal substances, the echinocandins anidulafungin, caspofungin, and micafungin, on the growth of Candida spp.
METHODS: The growth of 127 C. dubliniensis isolates and 103 C. albicans isolates cultured in medium containing anidulafungin, caspofungin, or micafungin was analyzed using a broth microdilution test according to the guidelines of the CLSI M27-A2 [NCCLS (1997), Wayne, PA]. The final concentrations of all three echinocandins ranged from 0.125 to 64 microg/L.
RESULTS: The different effects of these three antifungal substances on C. albicans cells in comparison to C. dubliniensis cells were quite distinct. When both Candida species were grown in the presence of anidulafungin only a trailing effect was observed. Micafungin induced an Eagle effect in C. dubliniensis only (63%), while caspofungin induced this effect in the majority of C. dubliniensis isolates (90%) and in only a few C. albicans isolates (14%).
CONCLUSIONS: Based on our observations, anidulafungin has effects that are different from the ones produced by micafungin and caspofungin. Whether this different response to high concentrations of echinocandins is based on genetic or phenotypic differences between C. albicans and C. dubliniensis has to be determined in future experiments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057972     DOI: 10.1007/s10096-007-0411-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

1.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

2.  Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.

Authors:  M A Pfaller; S Wey; T Gerarden; A Houston; R P Wenzel
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

3.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

4.  Studies of the paradoxical effect of caspofungin at high drug concentrations.

Authors:  David A Stevens; Theodore C White; David S Perlin; Claude P Selitrennikoff
Journal:  Diagn Microbiol Infect Dis       Date:  2005-03       Impact factor: 2.803

5.  Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.

Authors:  O Marchetti; P Moreillon; M P Glauser; J Bille; D Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.

Authors:  R Arai; T Sugita; A Nishikawa
Journal:  Mycoses       Date:  2005-01       Impact factor: 4.377

7.  In vitro studies of aculeacin A, a new antifungal antibiotic.

Authors:  K Iwata; Y Yamamoto; H Yamaguchi; T Hiratani
Journal:  J Antibiot (Tokyo)       Date:  1982-02       Impact factor: 2.649

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

10.  Rapid and unequivocal differentiation of Candida dubliniensis from other Candida species using species-specific DNA probes: comparison with phenotypic identification methods.

Authors:  A N B Ellepola; S F Hurst; C M Elie; C J Morrison
Journal:  Oral Microbiol Immunol       Date:  2003-12
View more
  34 in total

1.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Frequency of paradoxical effect with caspofungin in Candida albicans.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

3.  Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.

Authors:  Mohamed Khlif; Hervé Bogreau; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 4.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

5.  In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms.

Authors:  Tsun Sheng N Ku; Stella M Bernardo; Samuel A Lee
Journal:  J Med Microbiol       Date:  2011-06-23       Impact factor: 2.472

6.  Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

Authors:  Ryan K Shields; M Hong Nguyen; Chen Du; Ellen Press; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

7.  Identification of potent bactericidal compounds produced by escapin, an L-amino acid oxidase in the ink of the sea hare Aplysia californica.

Authors:  Ko-Chun Ko; Binghe Wang; Phang C Tai; Charles D Derby
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence.

Authors:  Elias Epp; Ghyslaine Vanier; Doreen Harcus; Anna Y Lee; Gregor Jansen; Michael Hallett; Don C Sheppard; David Y Thomas; Carol A Munro; Alaka Mullick; Malcolm Whiteway
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

9.  Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.

Authors:  Carla J Walraven; Stella M Bernardo; Nathan P Wiederhold; Samuel A Lee
Journal:  Med Mycol       Date:  2013-12-22       Impact factor: 4.076

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.